JP2019534891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534891A5 JP2019534891A5 JP2019529466A JP2019529466A JP2019534891A5 JP 2019534891 A5 JP2019534891 A5 JP 2019534891A5 JP 2019529466 A JP2019529466 A JP 2019529466A JP 2019529466 A JP2019529466 A JP 2019529466A JP 2019534891 A5 JP2019534891 A5 JP 2019534891A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- subject
- antibody
- seq
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374752P | 2016-08-13 | 2016-08-13 | |
| US62/374,752 | 2016-08-13 | ||
| PCT/US2017/046668 WO2018035001A1 (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534891A JP2019534891A (ja) | 2019-12-05 |
| JP2019534891A5 true JP2019534891A5 (https=) | 2020-09-24 |
Family
ID=61197201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529466A Pending JP2019534891A (ja) | 2016-08-13 | 2017-08-13 | Ｈａａｒｔ安定化患者におけるｃｄ４に対する抗体によるｈｉｖ感染症の処置および持続的ウイルス学的寛解 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11292839B2 (https=) |
| EP (1) | EP3497133A4 (https=) |
| JP (1) | JP2019534891A (https=) |
| KR (1) | KR20190071677A (https=) |
| CN (1) | CN109996815A (https=) |
| AU (1) | AU2017312887A1 (https=) |
| BR (1) | BR112019002734A2 (https=) |
| CA (1) | CA3033728A1 (https=) |
| MX (1) | MX2019001814A (https=) |
| RU (1) | RU2019106804A (https=) |
| SG (2) | SG11201901203PA (https=) |
| TW (1) | TW201808998A (https=) |
| WO (1) | WO2018035001A1 (https=) |
| ZA (1) | ZA201901374B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190071677A (ko) * | 2016-08-13 | 2019-06-24 | 유나이티드 바이오파마, 인크. | Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화 |
| US12384830B2 (en) | 2017-06-02 | 2025-08-12 | Regents Of The University Of Minnesota | Compositions and methods for improving immunotherapy |
| AU2020275049A1 (en) * | 2019-05-16 | 2022-01-06 | Nanjing Legend Biotech Co., Ltd. | Engineered immune cells comprsing a recognition molecule |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| EP4716750A1 (en) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381295A (en) | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
| DE3828582A1 (de) | 1988-08-23 | 1990-03-01 | Max Planck Gesellschaft | Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren |
| EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
| JPH0725794B2 (ja) | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | 新規なペプチド |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU662891B2 (en) | 1990-11-27 | 1995-09-21 | Biogen Idec Ma Inc. | Anti CD-4 antibodies blocking HIV-induced syncytia |
| JPH06125783A (ja) | 1991-12-28 | 1994-05-10 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ抗体およびその調製方法 |
| DE69535002T2 (de) | 1994-03-08 | 2006-12-07 | Memorial Sloan-Kettering Cancer Center | Rekombinante humanisierte antikörper gegen fb5 |
| US5961976A (en) | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| JP3231262B2 (ja) | 1996-06-05 | 2001-11-19 | 株式会社ビー・エム・エル | ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 |
| US5962319A (en) | 1997-05-19 | 1999-10-05 | Bml, Inc. | Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene |
| JPH10155489A (ja) | 1996-11-27 | 1998-06-16 | Asahi Chem Ind Co Ltd | 組換え抗体及びそれをコードする核酸 |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1083226A4 (en) | 1998-05-25 | 2001-12-19 | Asahi Chemical Ind | DEVICE FOR SEPARATING CELLS AND SEPARATION METHOD. |
| US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| CO5160259A1 (es) | 1999-03-02 | 2002-05-30 | Schering Corp | Interferon alfa pegilado en la terapia contra el hiv |
| CA2469901C (en) | 2001-12-11 | 2017-07-04 | Biotectid Gmbh | Use of a labelled ligand having specificity for the human cd4 molecule to produce a diagnostic agent for analysing migration and/or distribution patterns of cell populations |
| JP2003327536A (ja) | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | ヒト免疫不全症候群ウイルスの感染、増殖抑制剤 |
| US20030211470A1 (en) | 2002-03-15 | 2003-11-13 | Olson William C. | CD4-IgG2-based salvage therapy of HIV-1 infection |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| US20090232826A1 (en) | 2005-05-02 | 2009-09-17 | Mymetics Corporation | Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2 |
| RU2393873C2 (ru) | 2005-05-02 | 2010-07-10 | Майметикс Корпорейшн | Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2 |
| WO2007025276A2 (en) | 2005-08-25 | 2007-03-01 | Government Of The United States Of America, As Represented By The Secretary | Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies |
| WO2007094983A2 (en) | 2006-02-03 | 2007-08-23 | Tanox, Inc. | Methods and compositions for the inhibition of hiv infection of t cells |
| CA2884430A1 (en) | 2012-09-07 | 2014-03-13 | Baylor Research Institute | Hiv vaccine compositions and methods |
| SMT202100464T1 (it) | 2013-03-14 | 2021-11-12 | Macrogenics Inc | Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione |
| AU2014269042A1 (en) * | 2013-05-24 | 2015-12-03 | Cooper Human Systems Llc | Methods and compositions for treatment of HIV infection |
| MX2017003546A (es) | 2014-09-16 | 2017-08-14 | Ubi Ip Holdings | Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih. |
| KR20190071677A (ko) * | 2016-08-13 | 2019-06-24 | 유나이티드 바이오파마, 인크. | Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화 |
-
2017
- 2017-08-13 KR KR1020197007296A patent/KR20190071677A/ko not_active Ceased
- 2017-08-13 US US16/325,361 patent/US11292839B2/en active Active
- 2017-08-13 SG SG11201901203PA patent/SG11201901203PA/en unknown
- 2017-08-13 AU AU2017312887A patent/AU2017312887A1/en not_active Abandoned
- 2017-08-13 RU RU2019106804A patent/RU2019106804A/ru not_active Application Discontinuation
- 2017-08-13 WO PCT/US2017/046668 patent/WO2018035001A1/en not_active Ceased
- 2017-08-13 BR BR112019002734-3A patent/BR112019002734A2/pt unknown
- 2017-08-13 CN CN201780050119.1A patent/CN109996815A/zh active Pending
- 2017-08-13 CA CA3033728A patent/CA3033728A1/en active Pending
- 2017-08-13 SG SG10202100268RA patent/SG10202100268RA/en unknown
- 2017-08-13 EP EP17841919.8A patent/EP3497133A4/en not_active Withdrawn
- 2017-08-13 MX MX2019001814A patent/MX2019001814A/es unknown
- 2017-08-13 JP JP2019529466A patent/JP2019534891A/ja active Pending
- 2017-08-14 TW TW106127443A patent/TW201808998A/zh unknown
-
2019
- 2019-03-05 ZA ZA2019/01374A patent/ZA201901374B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534891A5 (https=) | ||
| US11292839B2 (en) | Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients | |
| JP6857498B2 (ja) | 癌を処置するための併用方法 | |
| AU2021203071B2 (en) | Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition | |
| Madan et al. | Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections | |
| US12427184B2 (en) | Treatment of immunosuppressed subjects | |
| JP2022514561A5 (https=) | ||
| US20250059280A1 (en) | Methods of treating human immunodeficiency virus (hiv) disease | |
| CN109833480A (zh) | 靶向nk细胞免疫检查点治疗感染性疾病的方法 | |
| US20220016079A1 (en) | Combination treatment of hiv infections | |
| US20260124277A1 (en) | Treatment of immunosuppressed subjects | |
| TW202540166A (zh) | 用於治療自體免疫性疾病／自體免疫性病症的ｃｄ１９選擇性ｔ細胞接合分子 | |
| Cao et al. | The Whole is Greater than the Sum of the Parts, Combination Use as CABENUVA in Treating HIV: Meta-Analysis from Clinical Datasets | |
| Rizza et al. | Novel HIV drugs and drug delivery strategies. A report from the 2018 Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA-March 4-7, 2018 | |
| Diaz-Torne et al. | AB0424 Il-6 receptor blockade induced a different immune response in rheumatoid arthritis patients with and without remission | |
| D'Cruz et al. | Recent advances in anogenital antiretroviral microbicides and multimodal delivery systems. | |
| HK40003703A (en) | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients | |
| RU2008106786A (ru) | Способы снижения вирусной нагрузки у пациентов, инфицированных вич-1 | |
| HK1114791A (en) | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome | |
| HK1115064A (en) | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |